Suchergebnisse - "Balar, Arjun V"

PubPharm (16)

1

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma : Results from PIVOT-02

enthalten in: European urology | 2022

von Siefker-Radtke, A. | Cho, D. | Diab, A. | +15

CommentIn: Eur Urol. 2022 Oct;82(4):374-376. - PMID 35752503

2

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer : A Multicenter, Single-Arm, Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Funt, S. | Lattanzi, M. | Whiting, K. | +36

CommentIn: J Clin Oncol. 2022 Aug 10;40(23):2656. - PMID 35609220

3

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma : results from the PIVOT-02 study

enthalten in: Journal for immunotherapy of cancer | 2022

von Tannir, N. | Cho, D. | Diab, A. | +15

4

TROPHY-U-01 : A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Tagawa, S. | Balar, A. | Petrylak, D. | +16

CommentIn: Nat Rev Clin Oncol. 2021 Jul;18(7):400. - PMID 33986521

5

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057) : an open-label, single-arm, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Balar, A. | Kamat, A. | Kulkarni, G. | +15

CommentIn: Nat Rev Urol. 2021 Oct;18(10):577-578. - PMID 34230659

6

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Yu, E. | Petrylak, D. | O'Donnell, P. | +17

CommentIn: Lancet Oncol. 2021 Jun;22(6):748-749. - PMID 33991513

7

PIVOT-10 : Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer

enthalten in: Future oncology (London, England) | 2021

von Huddart, R. | Siefker-Radtke, A. | Balar, A. | +15

8

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

9

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052) : Outcomes in Older Patients by Age and Performance Status

enthalten in: European urology oncology | 2020

von Grivas, P. | Plimack, E. | Balar, A. | +11

10

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Rosenberg, J. | O'Donnell, P. | Balar, A. | +10

CommentIn: J Clin Oncol. 2019 Oct 10;37(29):2587-2591. - PMID 31260641